Trial Profile
Long-term Safety Extension Study of Apremilast (CC-10004) in Subjects Who Completed the Treatment Phase of the Extension Study CC-10004-PSOR-005E [EXTENSION OF 700244254].
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 May 2014
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 12 May 2014 New trial record